Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H14N8O2 |
Molecular Weight | 314.3027 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1N(NC=C1N2C=CN=N2)C3=NC=NC(=C3)N4CCOCC4
InChI
InChIKey=IJMBOKOTALXLKS-UHFFFAOYSA-N
InChI=1S/C13H14N8O2/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19/h1-2,7-9,17H,3-6H2
Molecular Formula | C13H14N8O2 |
Molecular Weight | 314.3027 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molidustat also was known as BAY 85-3934 is a novel inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) which stimulates erythropoietin (EPO) production and the formation of red blood cells. Hypoxia-inducible factor (HIF) is the major transcription factor involved in erythropoietin gene expression. Because oxygen-dependent degradation of the α subunit of HIF suppresses erythropoietin expression, stimulation of erythropoiesis by agents that prevent degradation of HIF has been one strategy for managing anemia. Thus, molidustat is in phase II of a clinical trial to investigate the effects therapy in patients with renal anemia associated with chronic kidney disease and/or end-stage renal disease.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3028 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28242135 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02055482
Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25392999
BAY 85-3934 (molidustat) induced the transcription of hypoxia-sensitive genes in HeLa, A549, and Hep3B cells. The mRNA expression levels of a panel of HIF target genes were analyzed by quantitative RT-PCR (qRT-PCR) in the three cell lines 4 h after exposure to concentrations of BAY 85-3934 up to 10 µM. mRNA levels were found to be induced by BAY 85-3934 in a dose-dependent manner. The basal level of expression and the factor of induction varied considerably between cell lines. The highest induction factors (up to 20-fold) were observed for carbonic anhydrase IX (CA-IX) in HeLa cells, CA-IX and angiopoietin-like 4 (ANGPTL-4) in A549 cells, and EPO and ANGPTL-4 in Hep3B cells. The other genes examined were induced between 2- and 5-fold. The mRNA expression level of ANGPTL-4 was not increased by BAY 85-3934 in HeLa cells. EPO mRNA was not detectable at baseline and not induced in HeLa or A549 cells. The threshold concentration for induction of CA-IX expression was 500 nM in HeLa cells, and greater than 1 µM for all other genes that showed a response.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:32:50 GMT 2023
by
admin
on
Sat Dec 16 05:32:50 GMT 2023
|
Record UNII |
9JH486CZ13
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
59603622
Created by
admin on Sat Dec 16 05:32:50 GMT 2023 , Edited by admin on Sat Dec 16 05:32:50 GMT 2023
|
PRIMARY | |||
|
100000175261
Created by
admin on Sat Dec 16 05:32:50 GMT 2023 , Edited by admin on Sat Dec 16 05:32:50 GMT 2023
|
PRIMARY | |||
|
DTXSID80151089
Created by
admin on Sat Dec 16 05:32:50 GMT 2023 , Edited by admin on Sat Dec 16 05:32:50 GMT 2023
|
PRIMARY | |||
|
9JH486CZ13
Created by
admin on Sat Dec 16 05:32:50 GMT 2023 , Edited by admin on Sat Dec 16 05:32:50 GMT 2023
|
PRIMARY | |||
|
DB15642
Created by
admin on Sat Dec 16 05:32:50 GMT 2023 , Edited by admin on Sat Dec 16 05:32:50 GMT 2023
|
PRIMARY | |||
|
1154028-82-6
Created by
admin on Sat Dec 16 05:32:50 GMT 2023 , Edited by admin on Sat Dec 16 05:32:50 GMT 2023
|
PRIMARY | |||
|
Molidustat
Created by
admin on Sat Dec 16 05:32:50 GMT 2023 , Edited by admin on Sat Dec 16 05:32:50 GMT 2023
|
PRIMARY | |||
|
JK-106
Created by
admin on Sat Dec 16 05:32:50 GMT 2023 , Edited by admin on Sat Dec 16 05:32:50 GMT 2023
|
PRIMARY | |||
|
C174580
Created by
admin on Sat Dec 16 05:32:50 GMT 2023 , Edited by admin on Sat Dec 16 05:32:50 GMT 2023
|
PRIMARY | |||
|
9655
Created by
admin on Sat Dec 16 05:32:50 GMT 2023 , Edited by admin on Sat Dec 16 05:32:50 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |